PON3 — Paraoxonase 3

Migration, Crosslink

📖

PON3 — Paraoxonase 3

active

wiki page Created: 2026-04-02T07:19:32 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-pon3

📖 Wiki Page

gene1659 wordssynced 2026-04-02

PON3 — Paraoxonase 3

<div class="infobox infobox-gene">
| | |
|:---|:---|
| Gene Symbol | PON3 |
| Full Name | Paraoxonase 3 |
| Protein Name | Arylesterase 2 |
| Chromosomal Location | 7q21.3 |
| NCBI Gene ID | 5446 |
| OMIM ID | 605450 |
| Ensembl ID | ENSG00000005421 |
| UniProt ID | Q15166 |
| Protein Length | 354 amino acids |
| Signal Peptide | 26 amino acids (secreted) |
</div>

Overview

PON3 (Paraoxonase 3) encodes a member of the paraoxonase gene family, which also includes PON1 and PON2. These enzymes are characterized by their ability to hydrolyze organophosphates and their association with high-density lipoprotein (HDL) particles. While PON1 and PON2 have been extensively studied, PON3 remains the least characterized member of the family, though emerging research reveals important roles in antioxidant defense, lipid metabolism, and cellular protection. [@rodriguezcarreno2014]

PON3 is a secreted glycoprotein that associates with HDL particles in plasma, contributing to the anti-atherogenic properties of HDL. The enzyme exhibits both paraoxonase activity (hydrolyzing the toxic organophosphate paraoxon) and arylesterase activity (hydrolyzing phenyl acetate). Additionally, PON3 has lactonase activity, enabling it to hydrolyze oxidized lipid-derived lactones and prevent the propagation of oxidative damage. These activities position PON3 as an important component of the antioxidant defense system, with implications for neurodegenerative diseases, cardiovascular disease, and metabolic disorders. [@marsillach2011]

...

PON3 — Paraoxonase 3

<div class="infobox infobox-gene">
| | |
|:---|:---|
| Gene Symbol | PON3 |
| Full Name | Paraoxonase 3 |
| Protein Name | Arylesterase 2 |
| Chromosomal Location | 7q21.3 |
| NCBI Gene ID | 5446 |
| OMIM ID | 605450 |
| Ensembl ID | ENSG00000005421 |
| UniProt ID | Q15166 |
| Protein Length | 354 amino acids |
| Signal Peptide | 26 amino acids (secreted) |
</div>

Overview

PON3 (Paraoxonase 3) encodes a member of the paraoxonase gene family, which also includes PON1 and PON2. These enzymes are characterized by their ability to hydrolyze organophosphates and their association with high-density lipoprotein (HDL) particles. While PON1 and PON2 have been extensively studied, PON3 remains the least characterized member of the family, though emerging research reveals important roles in antioxidant defense, lipid metabolism, and cellular protection. [@rodriguezcarreno2014]

PON3 is a secreted glycoprotein that associates with HDL particles in plasma, contributing to the anti-atherogenic properties of HDL. The enzyme exhibits both paraoxonase activity (hydrolyzing the toxic organophosphate paraoxon) and arylesterase activity (hydrolyzing phenyl acetate). Additionally, PON3 has lactonase activity, enabling it to hydrolyze oxidized lipid-derived lactones and prevent the propagation of oxidative damage. These activities position PON3 as an important component of the antioxidant defense system, with implications for neurodegenerative diseases, cardiovascular disease, and metabolic disorders. [@marsillach2011]

Protein Structure and Function

Structural Features

The PON3 protein (354 amino acids, ~39 kDa) shares structural features with other paraoxonase family members:

N-terminal signal peptide: 26 amino acids directing secretion
Six-bladed β-propeller: Central structural motif characteristic of the paraoxonase family
Active site: Conserved serine hydrolase active site with catalytic triad
Calcium-binding sites: Two calcium ions required for structural stability and activity
Free thiol at Cys284: Critical for enzymatic activity
Hydrophobic patch: Mediates HDL association

The enzyme is glycosylated at multiple sites, with N-linked carbohydrates contributing to its stability and function. The structure enables substrate access to the active site while maintaining proper folding and secretion. [@gupta2011]

Enzymatic Activities

PON3 exhibits multiple enzymatic activities:

Paraoxonase activity: Hydrolyzes organophosphates including paraoxon (the toxic metabolite of parathion). This activity is weaker than PON1 but still functionally relevant.

Arylesterase activity: Hydrolyzes phenyl acetate to phenol and acetate. This is considered the "natural" substrate activity and is often used for quantification.

Lactonase activity: Hydrolyzes oxidized lipid-derived lactones, particularly those formed during lipid peroxidation. This activity is critical for anti-atherogenic and neuroprotective functions. [@morin2014]

Thiolactonase activity: Specific for homocysteine thiolactone, which is toxic to endothelial cells and proteins.

Substrate Specificity

PON3 displays substrate preferences:

Best substrate: Aryl esters (phenyl acetate)
Organophosphates: Lower activity than PON1
Lactones: Similar to PON1, hydrolyzes oxidized phospholipid-derived lactones
Specificity differences: Distinct substrate profile from PON1 and PON2

Expression Pattern

Tissue Distribution

PON3 exhibits distinct tissue distribution:

Liver: Primary expression site, synthesized in hepatocytes
Plasma: Circulates associated with HDL particles
Kidney: Moderate expression
Brain: Lower expression, with regional variation
Intestine: Some expression
Lung: Detectable expression

Cell-type specificity:

Hepatocytes: Primary source of circulating PON3
Neurons: Low baseline expression, may increase under stress
Astrocytes: Expression contributes to brain antioxidant capacity
Endothelial cells: Expression may provide vascular protection

Regulation

Multiple factors regulate PON3 expression:

Transcriptional regulation: PPAR-α agonists increase expression

Hormonal regulation: Estrogen affects hepatic expression

Dietary factors: High-fat diet may reduce expression

Oxidative stress: May induce expression as protective response

Developmental patterns: Age-related changes in expression

Role in Neurodegenerative Diseases

Alzheimer's Disease

PON3 is implicated in Alzheimer's disease through multiple mechanisms:

HDL-associated antioxidant activity: PON3 contributes to HDL's ability to prevent LDL oxidation. In AD, HDL function is impaired, and PON3 reduction may exacerbate oxidative damage. [@she2011]

Lipid peroxidation prevention: The lactonase activity prevents formation of toxic lipid peroxidation products that contribute to amyloid toxicity and neuronal damage.

Amyloid-beta interactions: HDL and associated proteins including PON3 may influence Aβ metabolism and clearance.

Synaptic protection: PON3 may protect synaptic membranes from oxidative damage, preserving synaptic function.

Neuroinflammation: By preventing oxidative stress, PON3 may reduce microglial activation and neuroinflammatory responses.

Studies have reported reduced PON3 expression in AD brain tissue, particularly in regions vulnerable to pathology. The enzyme's decline may contribute to the increased oxidative stress observed in AD brains. [@liu2018]

Parkinson's Disease

Dopaminergic neuron protection: The substantia nigra is particularly vulnerable to oxidative stress. PON3 may provide antioxidant protection to dopaminergic neurons. [@schrader2006]

α-Synuclein aggregation: Oxidative stress promotes α-synuclein aggregation. PON3's antioxidant activity may reduce this trigger.

Mitochondrial protection: Oxidative damage to mitochondria contributes to PD pathogenesis. PON3 may help preserve mitochondrial function.

Neuroinflammation: Reduced oxidative stress may decrease microglial activation in PD.

Other Neurodegenerative Conditions

Amyotrophic Lateral Sclerosis (ALS): Altered paraoxonase expression reported, potential for therapeutic intervention
Huntington's Disease: Oxidative stress contributes to neuronal dysfunction; PON3 may provide protection
Multiple Sclerosis: Demyelination involves oxidative damage; PON3's role under investigation
Aging: Age-related decline in PON3 may contribute to increased oxidative stress vulnerability

Antioxidant Mechanisms

HDL-Mediated Protection

PON3 contributes to HDL's antioxidant functions:

Prevention of LDL oxidation: PON3 directly inhibits copper-catalyzed LDL oxidation

Hydrolysis of oxidized phospholipids: Neutralizes pro-inflammatory oxidized phospholipids

Protection of HDL particles: Prevents HDL oxidation itself

Synergy with other HDL proteins: Works with PON1, apolipoprotein A-I

Cellular Protection

PON3 provides cellular-level protection:

Membrane protection: Prevents lipid peroxidation in cellular membranes

Enzyme protection: Preserves function of other proteins through reduction of oxidative damage

DNA protection: May reduce oxidative DNA damage

Subcellular organelle protection: Particularly relevant for mitochondria and endoplasmic reticulum

Molecular Mechanisms

Lactones as substrates: Hydrolyzes toxic lipid lactones before they cause damage
Free radical scavenging: Direct antioxidant activity
Preservation of endogenous antioxidants: Prevents oxidation of cellular antioxidant systems

Cardiovascular Implications

Atherosclerosis

PON3 has significant cardiovascular relevance:

Anti-atherogenic HDL: Contributes to HDL's protective functions

Endothelial protection: Prevents oxidative damage to endothelial cells

Plaque stabilization: May reduce oxidative processes in atherosclerotic lesions

Coronary artery disease: Reduced activity associated with disease

Relationship with PON1

PON3 and PON1 have complementary functions:

Different substrate preferences: Complementary enzymatic activities
Synergistic protection: Both contribute to HDL antioxidant capacity
Differential regulation: Responds differently to various stimuli
Coordinate protective effects: Both reduced in some disease states

Signaling and Interactions

Protein Interactions

HDL particles: Primary association with apolipoprotein A-I-containing HDL
Apolipoprotein A-I (APOA1): Major structural protein of HDL
Other HDL-associated proteins: Coordinate functions within HDL
Cell surface receptors: May interact with SR-B1 and other HDL receptors

Pathway Involvement

Lipid metabolism: Modulates HDL metabolism and function
Oxidative stress response: Part of cellular antioxidant defense
Inflammatory signaling: Affects NF-κB and other inflammatory pathways
Endothelial function: Maintains vascular endothelial health

Therapeutic Implications

Therapeutic Strategies

Targeting PON3 for therapeutic benefit:

Recombinant PON3: Development of enzyme replacement therapy

Gene therapy: AAV-mediated PON3 expression

Small molecule activators: Compounds that enhance PON3 activity

HDL-based therapies: HDL infusions or mimetics

Combination approaches: Combined with other antioxidant strategies

Challenges

Secretory nature: Requires efficient secretion systems
Stability: Maintaining enzyme activity in circulation
Delivery: Achieving adequate brain delivery for neurodegenerative applications
Specificity: Achieving cell-type specific targeting

Research Directions

Developing PON3-based therapeutics
Understanding structure-activity relationships
Identifying safe and effective activators
Exploring gene therapy approaches

Genetic Considerations

Polymorphisms

PON3 genetic variants have been studied:

Coding variants: Affect enzymatic activity
Promoter variants: Influence expression levels
Linkage with PON1/PON2: Haplotype structure

Disease Associations

Cardiovascular disease: Some variants associated with risk
Neurodegenerative disease: Investigation ongoing
Metabolic syndrome: Association with lipid metabolism

Research Methods

Enzyme activity assays: Arylesterase and lactonase measurements
Protein quantification: ELISA and Western blot
Gene expression analysis: qPCR, RNA-seq
Histochemistry: Immunostaining in tissue sections
Functional studies: Cell culture and animal models

External Links

[NCBI Gene: PON3](https://www.ncbi.nlm.nih.gov/gene/5446)
[UniProt: Q15166](https://www.uniprot.org/uniprot/Q15166)
[Ensembl: ENSG00000005421](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000005421)
[OMIM: 605450](https://www.omim.org/entry/605450)

Brain Atlas Resources

[Allen Human Brain Atlas - PON3](https://human.brain-map.org/microarray/search/show?search_term=PON3)
[BrainSpan Atlas - PON3 Expression](https://www.brainspan.org/search?gene=PON3)

References

[Rodriguez-Carreno A et al., PON3: an antioxidant enzyme (2014)](https://pubmed.ncbi.nlm.nih.gov/25069385/)

[Marsillach J et al., The role of paraoxonase-3 in HDL function and antioxidant activity (2011)](https://pubmed.ncbi.nlm.nih.gov/21616067/)

[Marsillach J et al., Paraoxonase-3 in disease (2014)](https://pubmed.ncbi.nlm.nih.gov/25224449/)

[Berrougui H et al., PON3-mediated antioxidant activity in HDL (2006)](https://pubmed.ncbi.nlm.nih.gov/16413441/)

[Aviram M et al., Paraoxonases and cardiovascular disease (2004)](https://pubmed.ncbi.nlm.nih.gov/15100264/)

[Dullaart RP et al., PON3 and HDL function in atherosclerosis (2010)](https://pubmed.ncbi.nlm.nih.gov/20134031/)

[Morin B et al., PON3 lactonase activity and neuroprotection (2014)](https://pubmed.ncbi.nlm.nih.gov/24211735/)

[Ng CJ et al., PON3 in inflammation and atherosclerosis (2012)](https://pubmed.ncbi.nlm.nih.gov/22513578/)

[She ZG et al., PON3 expression in Alzheimer's disease brain (2011)](https://pubmed.ncbi.nlm.nih.gov/21606573/)

[Liu Q et al., PON3 and lipid metabolism in neurodegeneration (2018)](https://pubmed.ncbi.nlm.nih.gov/29625248/)

[Gupta N et al., PON3: structure, function and regulation (2011)](https://pubmed.ncbi.nlm.nih.gov/21145620/)

[Wenzel K et al., PON3 and oxidative stress in neurodegeneration (2016)](https://pubmed.ncbi.nlm.nih.gov/27586041/)

[Hummel N et al., PON3 in plasma and brain (2011)](https://pubmed.ncbi.nlm.nih.gov/21739457/)

[Stin J et al., Paraoxonase gene family and neurodegenerative disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32038228/)

[Shih DM et al., PON3 and the defense against oxidative stress (2015)](https://pubmed.ncbi.nlm.nih.gov/26163056/)

[Levy E et al., PON3 in lipid rafts and neuronal function (2019)](https://pubmed.ncbi.nlm.nih.gov/30600564/)

[Schrader C et al., PON3 in Parkinson's disease (2006)](https://pubmed.ncbi.nlm.nih.gov/16631747/)

[Zhang Q et al., PON3 and the blood-brain barrier (2019)](https://pubmed.ncbi.nlm.nih.gov/31016557/)

[Reddy VS et al., PON3 in aging and age-related disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34013652/)

[Chen X et al., PON3 genetic variants and disease risk (2022)](https://pubmed.ncbi.nlm.nih.gov/35135892/)

📖 View canonical wiki page →

Related Entities

PON3

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-pon3
kg_node_id	PON3
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-9e96064a32e5
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-pon3'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

5%

Debates

0

Incoming

1

Outgoing

3

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

PON3 — Paraoxonase 3

PON3 — Paraoxonase 3

Overview

PON3 — Paraoxonase 3

Overview

Protein Structure and Function

Structural Features

Enzymatic Activities

Substrate Specificity

Expression Pattern

Tissue Distribution

Regulation

Role in Neurodegenerative Diseases

Alzheimer's Disease

Parkinson's Disease

Other Neurodegenerative Conditions

Antioxidant Mechanisms

HDL-Mediated Protection

Cellular Protection

Molecular Mechanisms

Cardiovascular Implications

Atherosclerosis

Relationship with PON1

Signaling and Interactions

Protein Interactions

Pathway Involvement

Therapeutic Implications

Therapeutic Strategies

Challenges

Research Directions

Genetic Considerations

Polymorphisms

Disease Associations

Research Methods

See Also

External Links

Brain Atlas Resources

References

💬 Discussion